Is COVID‐19 Vaccination Beneficial for Tumor Patients: A Cross‐Sectional Investigation in China

Abstract

ABSTRACT Introduction Tumor patients take a high risk of SARS‐CoV‐2 infection, high incidence of serious events, poor prognosis and high mortality in the coronavirus disease 2019 (COVID‐19) epidemic, but there is still lack of supporting evidence that the COVID‐19 vaccination is beneficial for tumor patients to encourage them to receive the vaccination. Methods A cross‐sectional study was conducted in Shantou, China and questionnaires were collected in the hospitals from February 13, 2023 to April 23, 2023. Using the receiving of COVID‐19 vaccination as the primary outcome, descriptive, univariate and multivariate analyses were generated. Results 161 out of 241 patients (66.80%) had received at least one dose of COVID‐19 vaccine and 61.00% patients had been infected with SARS‐CoV‐2. Patients with general symptoms (p = 0.013) and others (p = 0.022) had a higher proportion of nonvaccinated patients than vaccinated ones. In the multivariate analysis, age (aOR = 0.971, 95% CI = 0.946–0.997, p = 0.031), the cognition of vaccines' impact on tumor treatment (aOR = 4.475, 95% CI = 1.772–11.299, p = 0.002), time since tumor diagnosis (aOR = 4.586, 95% CI = 2.122–9.909, p < 0.001) were identified as factors of COVID‐19 vaccination uptake. Conclusion COVID‐19 vaccination in China offers numerous advantages for tumor patients, helping to alleviate symptoms following infection and potentially decreasing the chances of tumor metastasis and recurrence.

Keywords

• benefits
• COVID‐19
• tumor
• uptake
• vaccination